AMRX Earnings & Financial Statements
Amneal Pharmaceuticals, Inc.
$18.90
-$0.67(-3.42%)
65
Overall
40
Value
91
Tech
65
Quality
Market Cap
$6.58B
Volume
3.48M
52W Range
$9.56 - $21.18
Target Price
$22.00
AMRX earnings and financial statements: Amneal Pharmaceuticals, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
AMRX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $3.02B | $2.79B | $2.39B | $2.21B | $2.09B |
| Cost of revenue | $1.91B | $1.77B | $1.57B | $1.43B | $1.32B |
| Operating income | $394.10M | $249.33M | $204.37M | -$94.93M | $152.72M |
| EBITDA | $402.73M | $232.68M | $181.96M | $159.02M | $401.10M |
| Net income | $72.06M | -$116.89M | -$83.99M | -$129.99M | $10.62M |
| EPS (diluted) | $0.22 | $-0.38 | $-0.48 | $-0.86 | $0.07 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $3.68B | $3.50B | $3.47B | $3.80B | $3.94B |
| Total liabilities | $2.69B | $2.60B | $2.68B | $2.83B | $3.43B |
| Shareholders’ equity | -$70.79M | -$109.27M | $19.78M | $298.42M | $360.34M |
| Cash and equivalents | $282.03M | $110.55M | $91.54M | $25.98M | $247.79M |
| Long-term debt | $2.57B | $2.16B | $2.39B | $2.59B | $2.72B |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $339.99M | $295.10M | $345.58M | $65.10M | $241.82M |
| Capital expenditure | -$85.58M | -$66.57M | -$69.19M | -$90.59M | -$52.64M |
| Free cash flow | $254.41M | $228.53M | $279.97M | -$25.50M | $189.18M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | AMRX | $18.90 | -3.4% | 3.48M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Amneal Pharmaceuticals, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW